Comparative Pharmacology
Head-to-head clinical analysis: MIRABEGRON versus MYRBETRIQ GRANULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRABEGRON versus MYRBETRIQ GRANULES.
MIRABEGRON vs MYRBETRIQ GRANULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder filling.
Beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder filling.
50 mg orally once daily, with or without food.
50 mg orally once daily, with or without food. May increase to 50 mg once daily if needed; maximum 50 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours, allowing once-daily dosing; steady state reached after 7 days.
Clinical Note
moderateMirabegron + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Doxycycline
Terminal elimination half-life: 50 hours (range 32-80 hours). Clinically, steady-state is achieved within 7 days with once-daily dosing.
Approximately 55% of the dose is excreted unchanged in urine, with 45% metabolized; fecal excretion accounts for about 22% (mainly as metabolites).
Primarily via hepatic metabolism; renal excretion accounts for 55-60% of total clearance, with <15% unchanged in urine. Biliary/fecal elimination: 40-45% of administered dose recovered in feces, mostly as metabolites.
Category A/B
Category C
Beta-3 Adrenergic Agonist
Beta-3 Adrenergic Agonist
"The metabolism of Doxycycline can be decreased when combined with Mirabegron."